Trial
NCT04394936
An Explorative Psoriasis Biomarker Study
UnknownTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Centre for Human Drug Research, Netherlands
Collaborators
Janssen Pharmaceuticals
Condition
Psoriasis Vulgaris
Intervention
Guselkumab
Why stopped
Early termination was initiated as the recruitment of the remaining 14 moderate-to-severe patients stagnated.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-15